Longeveron (LGVN) Cash from Operations (2020 - 2026)
Longeveron (LGVN) posted quarterly Cash from Operations of 4370000.0 for Q1 2026, up 6.96% year-over-year from 4085567.28 in Q1 2025, and up 17.48% quarter-over-quarter from 5296000.0 in Q4 2025.
Longeveron (LGVN) Cash from Operations (2020 - 2026) Analysis & Trends
Longeveron's Cash from Operations history runs 7 years deep, the most recent figure standing at 4370000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 6.96% year-over-year to 4370000.0; the TTM figure through Mar 2026 stood at 18318000.0 (down 18.34% YoY), while the FY2025 annual figure was 18645000.0, down 34.45% from the prior year.
- Cash from Operations for Q1 2026 stood at 4370000.0, up from 5296000.0 in the prior quarter.
- The five-year high for Cash from Operations was 2308000.0 in Q4 2022, with the low at 5848000.0 in Q1 2023.
- The 5-year median for Cash from Operations is 4234000.0 (2022), against an average of 4109058.82.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations tumbled 80.17% in 2022, then surged 47.23% in 2024.
- Longeveron's Cash from Operations stood at 2308000.0 in 2022, then slumped by 73.18% to 3997000.0 in 2023, then gained by 15.61% to 3373000.0 in 2024, then slumped by 57.01% to 5296000.0 in 2025, then increased by 17.48% to 4370000.0 in 2026.
- Business Quant data shows LGVN's Cash from Operations at 4370000.0 in Q1 2026, 5296000.0 in Q4 2025, and 5055000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | -5.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.65 Mn |
| Jun 30, 2026 | -5.65 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Mar 31, 2026 | -4.37 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Dec 31, 2025 | -5.30 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Jun 30, 2025 | -3.60 Mn |
| Mar 31, 2025 | -4.70 Mn |
| Mar 31, 2025 | -4.70 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Dec 31, 2024 | -3.37 Mn |
| Sep 30, 2024 | -2.84 Mn |
| Sep 30, 2024 | -2.84 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Jun 30, 2024 | -4.57 Mn |
| Mar 31, 2024 | -3.09 Mn |
| Mar 31, 2024 | -3.09 Mn |